The shelves in Pakistani pharmacies are increasingly barren. Life-saving drugs, ranging from basic antibiotics and heart medications to critical treatments for epilepsy, have vanished. While headlines frequently blame supply chain disruptions or global inflation, the actual culprit is a rigid, outdated system of government-mandated drug pricing that has trapped the industry in a death spiral.
At the heart of the crisis lies the Drug Regulatory Authority of Pakistan (DRAP). By maintaining strict price controls on essential medicines, the state has effectively rendered the production of these items unprofitable. When the cost of importing Active Pharmaceutical Ingredients (APIs)—mostly denominated in dollars—surpasses the maximum retail price set by the government, manufacturers face a binary choice: stop production or face bankruptcy. Read more on a related issue: this related article.
The Economics of Manufacturing Collapse
Pharmaceutical production operates on thin margins. When a company imports raw materials, it must account for exchange rate volatility, freight insurance, and energy costs. In Pakistan, the local currency has seen significant devaluation over the past few years. If the cost of the raw chemical components rises by 40% due to currency fluctuations, but the regulator refuses to adjust the retail price to reflect these costs, the manufacturer is forced to sell at a loss.
A hypothetical manufacturer, for instance, might produce an essential blood pressure medication for which the government has capped the price at 500 rupees per pack. If the manufacturing cost—accounting for the depreciated rupee—climbs to 550 rupees, the company cannot legally sell the product. Instead of absorbing the loss indefinitely, the firm halts production lines. This is not corporate greed; it is basic accounting. More analysis by Reuters delves into comparable views on the subject.
Regulatory Inertia and Political Fear
The government approaches drug pricing through the lens of political survival rather than economic reality. Officials fear that allowing pharmaceutical companies to raise prices will trigger public backlash, especially when inflation is already eroding household incomes. This fear results in long periods of regulatory paralysis where pricing files sit on desks for months.
By the time an adjustment is granted, the currency may have devalued further, rendering the approved price increase insufficient once again. This reactive, stop-start approach denies companies the predictability they need to invest in long-term inventory or domestic API manufacturing. The result is a cycle of artificial scarcity. Shortages drive up the prices on the black market, where desperate patients pay double or triple the intended retail price to secure medication from unscrupulous middlemen, proving that the government’s attempt to protect the consumer has ultimately made the burden heavier.
The Import Dependence Trap
Pakistan’s reliance on foreign raw materials exacerbates the vulnerability of its healthcare sector. The industry is not self-sufficient; it is an assembly operation heavily dependent on Chinese and Indian chemical precursors. When global supply chains tighten, or when the local banking sector struggles to open Letters of Credit (LCs) for pharmaceutical imports due to dwindling foreign exchange reserves, the system halts.
For years, policy experts have urged a shift toward local API manufacturing to insulate the country from international price shocks. However, the regulatory environment acts as a deterrent to such investment. Why would a firm invest millions in a domestic chemical synthesis plant when the final product is subject to price caps that do not reflect the true cost of production or the risks of capital investment? Without a transition to a flexible, market-based pricing mechanism that allows for periodic indexation against inflation and exchange rates, the domestic manufacturing sector will continue to atrophy.
The Human Toll Beyond the Statistics
Data points regarding stock-outs hide the visceral experience of the average patient. A parent searching three cities for a specific pediatric antibiotic or a chronic patient skipping doses to stretch a dwindling supply represent the failure of the state to ensure the most basic public good.
The crisis is not merely about pharmaceutical policy; it is a signal of institutional inability to manage essential markets. When the state mandates that a product must be sold below its cost of production, it ensures the product will eventually disappear. The marketplace demands honesty in pricing. Until the regulatory framework acknowledges that medicine is a commodity subject to the same economic laws as grain or fuel, the gap between the patient’s need and the availability of medicine will continue to widen. Addressing this requires the difficult political task of deregulating non-essential drug tiers while creating a transparent, automated mechanism for essential price adjustments that bypasses bureaucratic stagnation. Without these structural changes, the current medicine shortage will continue to haunt hospitals and homes, claiming lives not because the medicine is unavailable globally, but because the system has made it impossible to move across the border.
